9999999997-12-007829.txt : 20120417 9999999997-12-007829.hdr.sgml : 20120417 20120415141857 ACCESSION NUMBER: 9999999997-12-007829 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120417 DATE AS OF CHANGE: 20120415 20120417 20120415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELL THERAPEUTICS INC CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-12465 FILM NUMBER: 12759762 BUSINESS ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.%P94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]087)E;G0@."`P(%(O4F5S;W5R8V5S M(#$V(#`@4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH- M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I=G46:+TBBQO9B15![T>CXW[CR7\DD6KS&4.C"23[C.9`_U".4E?]NJ4 MD]1[9[>QDS93E88H9N1:[K^J?+O36";RN<3NO#:A0$ M$8P\TQ`WWB:$AVMKGA*$J:B;UH6>3:IMH4"2A*MR@?SGT/7'_IBR4V^ MUW5#?@Y:L8U.9:O0YU+ZVRJK-WFU)8]Y-:G:_/@]RYM67^]D`QX_RX*#QB%] MEYT'8X(DST\:"TJ;9V4K.Y9GGM[H7;OB`064@+IS*&CS/`^<#WK\SWHM@O-N MQQ6&`D+&0(C(+B^*K1?J8]]W?B(Z1@9!:&WN%7H\>W'YW.Z;^'ZG-I)W+[D3 M-;;&(.S\,#OV9S3KCP(8O@:0BO` MZ^_<72*NG_20.LM:QPXRY^9.NRR]-NH(["FTQ"&A9Z2=!,G!K,/34M15,Z0. M63ZOUG9JLO*!S;+N[H;$/P(,`'\UAY\-"F5N9'-TC%9M;^(X$/[.KQCIOC@G\,8A+V2_L;QTN=U2J:322>5T"L&`3R%A MG63;_OL;OP0"[:V.JL1V/,_,//.,S:>[%8-]U?N2]#XEB0<,DEV/>>#B'SZ& M;@B1.Z(C'Y)CSX4]_B>9^GKI$7"2?W`X8)0%D$SMPF!(X_BR.*"NRV)E9`4,`AJ1Q*&,C!.S.K.+X/R5_-$;A#2*@FM,#,Q@JH'" M7,TF3X^+9.'@;A\!8+R<`CH9TI#\.?DZ7M[9"4P>[N\7J]7B86G@(]H%5Y!# MA3VP(\QT?)(B!Q;UP7.1%9TFPSA'';M;8@(:ASZC&=H<7X.R2/LW%RCQ/+%AJ&P4U& M7DN\\IA\G4%+%Q(UL_3`>)+`PQQ8/%3L>\2W@%@)_Q>9LB%E_K6[X$Q@8!Q/ M>)Y#/3(:$.KAIW/AV%_^T,JQMTG)&YR#DL2PJH M+LS<#S%0F,Q_\T9N-#3A4:^C1_+W1Q^]$1O`-PV@*+2:\"_*=J]R9&V*EEIP M!EX4L$ZF)RFCQ%#5R;O.H=6=YLD3)C))T!GA&E]GG$ M%=:>%S;FVPZPDHQLW`<.L]>#V(BZ@KK$W.?*]8C`:/`-=JBK+6``<[Z132K? M0'>_&U+C(_G]G31Q2<&?A:%&%V6XY$M:&4C)D>4*D]%B'66FYJ5$VHJTT!.C:#P%64?1X1G2GMJVWB,\ MLKNZ5K692\ZWI7FGM+FXW6IK;5Q^IN*G:'M`BSZD7C?N=U1,2GDJI8ECKG/F<$!^MKSFTI`B"JQV4=9* M6S94@WI%\KFHS(1Z:C;8X_D;;$65Y67%L0,HP#C+2KG%YL[?^L!?;1OH4",: MAD'GGF!7S$;GLN]D>=3)[LH\+U_40<&-_->D6CMMC`;N*L9SU2STBT"QJLPV MV)EXQF$;XK4J><[3"F4U(A@:)ET?S&LP.:%?4]A:F"I:NQ.7HMR:&*H3S\1. M\.WG_]5E>$K[L;U,`=IN!D>W&W,I`X?%/EXL]4&6S?Y@W]RG,FO'V-5F@#?[ M"(>>BTBM;WT+7-QW/I?[P']?RMO&G]O$)ZI?5$%$I<365XU_H[[V'HC9!]<` MBTP<'XBOCR3+JDD+(S?]`T6C?"PVVQ=;+-D^U7=04Q]**>JWSRW)'_#^?M`2 M]&S)^:*X]/!@]B(?KS?UB%`/>T/Q>5[K;7:@5[BVP(&MQG?]H!V,DUH)]`,K M>E0SM9RVAH4QM(]S"=O(5FH=?PH8'/?B,&L'9T]GR+Q=L4%-3':EF34F(.NP M4GMCQ.==:YWDM90-=[.D]Z\``P#_)M8U#0IE;F1S=')E86T-96YD;V)J#3$@ M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I7!E+T]B:E-T;3X^R`(L'Z+G9V``$&`(V%"#<-"F5N9'-T7!E+UA-3"]4>7!E+TUE=&%D871A M/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H M:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,BXQ+6,P-#,@ M-3(N,S&UL;G,Z>&UP/2)H='1P M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AM<#I#&UP.D-R96%T M;W)4;V]L/@H@("`@("`@("`\>&UP.DUO9&EF>41A=&4^,C`Q,BTP-"TQ-50Q M-#HQ-RTP-#HP,#PO>&UP.DUO9&EF>41A=&4^"B`@("`@("`@(#QX;7`Z0W)E M871E1&%T93XR,#$R+3`T+3$U5#$T.C$W+3`T.C`P/"]X;7`Z0W)E871E1&%T M93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I M<'1I;VX@&UL.FQA;F<](G@M9&5F875L="(^36EC&UP34TZ26YS=&%N8V5)1#YU=6ED.C8R,S(R,SDR+6$X M-S(M-#=E,RTX9&-E+3)A-C(Q-C4R-S)B9CPO>&UP34TZ26YS=&%N8V5)1#X* M("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#POJ'5!:DZ@Q`B:=K@"P&!D8@P?0? M2#`R``08`'LF!1L-"F5N9'-T